Corcept Therapeutics Inc.

# Signal Note: Rock Springs Capital Initiates CORT Position Rock Springs' entry into CORT likely reflects conviction in mifepristone's sustained commercial trajectory following FDA retention in June 2023 and recent label expansion for Cushing's syndrome (KORLYM). The $1.7M position suggests selective conviction rather than a major conviction bet, potentially timed ahead of upcoming commercial milestones or competitive positioning as the oral glucocorticoid antagonist market develops.